Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

And since the drug works outside of the brain, it isn't associated with addiction. Vertex expects this approval to be the beginning of a multibillion-dollar franchise, and it's clear this story ...

Shares of Vertex Pharmaceuticals (NASDAQ ... It prevents pain signals from reaching the brain. A lack of activity in the brain makes Journavx a non-addictive solution for all types of moderate ...